ATM Inhibitor-8
ATM Inhibitor-8 (Compound 10r) is a highly potent, selective and orally active ATM inhibitor,with an IC50 of 1.15 nM. ATM Inhibitor-8 exhibits anti-tumor activity.
For research use only. We do not sell to patients.
- CAS No.: 2956666-60-5
- Formula: C26H34N6O2
- Molecular Weight:462.59
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
IC50:1.15 nM (ATM)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
>9 μM
Compound: 10r
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 6 days by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 6 days by MTT assay
|
[PMID: 37438997] |
| HCT-116 | IC50 |
1.69 nM
Compound: 10r
|
Inhibition of colony formation in human HCT-116 cells preincubated for 1 hr followed by exposure to 2 Gy gamma irradiation and measured after 1 week by crystal violet staining based chemiluminescence assay
Inhibition of colony formation in human HCT-116 cells preincubated for 1 hr followed by exposure to 2 Gy gamma irradiation and measured after 1 week by crystal violet staining based chemiluminescence assay
|
[PMID: 37438997] |
| MCF7 | IC50 |
>9 μM
Compound: 10r
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 6 days by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 6 days by MTT assay
|
[PMID: 37438997] |
| MCF7 | IC50 |
0.04 μM
Compound: 10r
|
Synergistic antiproliferative activity against human MCF7 cells assessed as Etoposide IC50 at 200 nM measured after 6 days by MTT assay
Synergistic antiproliferative activity against human MCF7 cells assessed as Etoposide IC50 at 200 nM measured after 6 days by MTT assay
|
[PMID: 37438997] |
| MCF7 | IC50 |
0.06 μM
Compound: 10r
|
Antiproliferative activity against human MCF7 cells assessed as irinotecan IC50 at 200 nM measured after 6 days by MTT assay
Antiproliferative activity against human MCF7 cells assessed as irinotecan IC50 at 200 nM measured after 6 days by MTT assay
|
[PMID: 37438997] |
| MCF7 | IC50 |
0.06 μM
Compound: 10r
|
Synergistic antiproliferative activity against human MCF7 cells assessed as irinotecan IC50 at 100 nM measured after 6 days by MTT assay
Synergistic antiproliferative activity against human MCF7 cells assessed as irinotecan IC50 at 100 nM measured after 6 days by MTT assay
|
[PMID: 37438997] |
| MCF7 | IC50 |
0.08 μM
Compound: 10r
|
Synergistic antiproliferative activity against human MCF7 cells assessed as Etoposide IC50 at 100 nM measured after 6 days by MTT assay
Synergistic antiproliferative activity against human MCF7 cells assessed as Etoposide IC50 at 100 nM measured after 6 days by MTT assay
|
[PMID: 37438997] |
| SW-620 | IC50 |
>9 μM
Compound: 10r
|
Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 6 days by MTT assay
Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 6 days by MTT assay
|
[PMID: 37438997] |
| SW-620 | IC50 |
0.02 μM
Compound: 10r
|
Synergistic inhibition of colony formation in human SW620 cells assessed as irinotecan IC50 at 200 nM preincubated for 1 hr followed by irinotecan addition and measured after 1 week by crystal violet staining based chemiluminescence assay
Synergistic inhibition of colony formation in human SW620 cells assessed as irinotecan IC50 at 200 nM preincubated for 1 hr followed by irinotecan addition and measured after 1 week by crystal violet staining based chemiluminescence assay
|
[PMID: 37438997] |
| SW-620 | IC50 |
0.22 μM
Compound: 10r
|
Synergistic antiproliferative activity against human SW620 cells assessed as irinotecan IC50 at 200 nM measured after 6 days by MTT assay
Synergistic antiproliferative activity against human SW620 cells assessed as irinotecan IC50 at 200 nM measured after 6 days by MTT assay
|
[PMID: 37438997] |
| SW-620 | IC50 |
0.35 μM
Compound: 10r
|
Synergistic antiproliferative activity against human SW620 cells assessed as irinotecan IC50 at 100 nM measured after 6 days by MTT assay
Synergistic antiproliferative activity against human SW620 cells assessed as irinotecan IC50 at 100 nM measured after 6 days by MTT assay
|
[PMID: 37438997] |
ATM Inhibitor-8 inhibits the proliferation of colorectal cancer cells (HCT116, SW620) and breast cancer cells (MCF-7) [1].
ATM Inhibitor-8(200 nM) inhibits the viability of MCF-7 cell combined with 4.22 μM Etposide (HY-13629) and 0.036 μM Irinotecan (HY-16562)[1].
ATM Inhibitor-8 (200 nM) inhibits the viability of SW620 cell with 0.22 μM Irinotecan (HY-16562) and inhibits cell colony with 0.02 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT116 cell[1]
-
Concentration:200 nM
-
Incubation Time:4 h
-
Result::Inhibted ATM pathway obviously combined with 25 μM Irinotecan.
-
Cell Line:HCT116 cell[1]
-
Concentration:200 nM
-
Incubation Time:48 h
-
Result:Decreased G0/G1 phase cells and increased G0/G1 phase cells with the concentration increase.
ATM Inhibitor-8(10 mg/kg, i.v.) has a good value of PK in Balb/c mice which means a lower plasma clearance , higher plasma exposure as well as excellent oral bioavailability. [1].
ATM Inhibitor-8 Pharmacokinetic Analysis in Balb/c Mice[1]
| Route | Dose (mg/kg) | Cmax (ng/mL) | Tmax (h) | t1/2 (h) | Clobs (L·h/kg) | Vss_obs (L/kg) | AUCINF_obs (ng·h/mL) | F (%) |
| i.v. | 10 | 6793.55 | 0.88 | 5.29 | 0.78 | 5.93 | 13027.01 | / |
| p.o. | 10 | 10216.65 | 0.33 | 3.37 | 0.73 | 3.52 | 13952.23 | 107.10 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mouse xenograft model of human colon cancer[1].
-
Dosage:40 mg/kg combined with Irinotecan(40 mg/kg)
-
Administration:ATM Inhibitor-8, 20 or 40 mg/kg, p.o. once daily for 3 days every week starting 24 h post-irinotecan dosing (40 mg/kg, i.p. once weekly).
-
Result:Inhibited tumor growth significantly.
Chemical Information
-
CAS No. 2956666-60-5
-
Molecular Weight 462.59
-
Formula C26H34N6O2
-
SMILES
CN(C1=NC2=CC(C3=CN=C(C=C3)OCCCN4CCCCC4)=CC=C2N=C1)C(NC(C)C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)